Navigation Links
Lung Cancer Rates Begin to Decline for U.S. Women
Date:9/16/2011

THURSDAY, Sept. 15 (HealthDay News) -- The rate of new lung cancer cases among American women is finally beginning to decline, much as it has for men in for years, a new U.S. government report shows.

New cases of lung malignancies fell by 2.2 percent per year on average for women between 2006 and 2008, after rising an average of 0.5 percent between 1999 and 2006, according to the U.S. Centers for Disease Control and Prevention.

Men's lung cancer incidence continued its long, slow decline, the agency added, but the pace of that decline has sped up in recent years. New cases fell by an average of 1.4 percent per year between 1999 and 2006 but that accelerated to a drop of nearly 3 percent per year by 2006-2008, the CDC said.

Between 1999 and 2008, declines in new lung cancer cases were seen among men in 35 states, while the rate remained stable in nine states. For women, six states -- California, Florida, Nevada, Oregon, Texas and Washington -- saw declines in lung cancer incidence during the same time period. Lung cancer rates for women remained stable in 24 states and they increased slightly in 14 states, the CDC team found.

While the trends are heartening, more needs to be done to stop the nation's number one cancer killer, said CDC Director Dr. Thomas R. Freiden. "Although lung cancer among men and women has decreased over the past few years, too many people continue to get sick and die from lung cancers, most of which are caused by smoking," he said in an agency news release. "The more we invest in proven tobacco control efforts, the fewer people will die from lung cancer."

Declines in lung cancer rates seemed closely tied to the fading popularity of lighting up. The report's authors note that lung cancers fell fastest in the West, where smoking among both men and women is lowest.

According to the reports' authors, certain moves by states seemed to result in steeper declines in lung cancer cases. The
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lung Cancer Rates Begin to Decline for U.S. Women
(Date:8/31/2015)... ... , ... Dental clinicians from Newcastle University, United Kingdom, visited ... more about its integrated approach to diabetes care. , Philip Preshaw, BDS, PhD, ... at Newcastle University, and Susan Bissett, National Institute for Health Research Clinical Research ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... registration for the company’s second Introduction to Hyperbaric Medicine Course. The next UHMS ... aboard the Queen Mary Hotel in Long Beach, CA. The meeting is open ...
(Date:8/31/2015)... ... 2015 , ... CareSource, a nonprofit Ohio-based health plan, has ... Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and media ... contributed to the company’s rapid growth. As the CareSource business model expands to ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published ... Reconstructive Surgery Global Open Journal that discusses the future of 3-D printing technology as ... the future, customized implants, prosthetics, and other 3-D printed tools could be used to ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael ... and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep ... hockey and served as team captain in both sports in his senior year. He ...
Breaking Medicine News(10 mins):Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3
... to maximize a ... woman,s chance for survival., EVERGREEN PARK, Ill., Nov. 16 In ... to,the American Cancer Society. Breast cancer is the most common cancer among,women, ... cancer,death in women, after lung cancer. Little Company of Mary Hospital ...
... Republic of Georgia Drug Agency Approves Protocol for New ... of Bavituximab in Combination ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage ... and,hepatitis C virus (HCV) infection, today announced that its ...
... ANGELES, Nov. 16 Neutrogena(R), a worldwide leader,in ... announced today that actress Diane Lane has signed ... Ms. Lane is a captivating and inspiring actress ... and daring spirit. In her new,role, she will ...
... antiemetic pharmaceutical drug (suitable for control of vomiting), ... This was the conclusion of clinical tests undertaken ... the results of which have been recently published ... The Oncologist . , Granisetrn is a ...
... Vaccine Efforts Stumble, Millions Remain Without AIDS Treatment ... ... time in,two weeks, clinical researchers working to develop an AIDS vaccine have,announced ... failed -- after Merck,s AIDS vaccine trial was halted last week,when its ...
... new alternative for patients with erosive gastroesophageal reflux disease ... (GERD) who cannot ... division of Wyeth (NYSE: WYE ), announced today that ... For Delayed-Release Oral Suspension, a new addition,to the Protonix family ...
Cached Medicine News:Health News:Web Site Helps Women Evaluate Risk of Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Health News:Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador 2Health News:Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy 2Health News:AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 3
(Date:8/31/2015)...  Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a ... of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, ... four investor conferences in September. , ... Company, LLC Emerging Growth Conference in ... , President & Chief Executive Officer, will present a ...
(Date:8/31/2015)... Israel , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the ... commercializes biomedical innovations in ophthalmology and cancer diagnostics, ... Technologies (TASE: MCTC), has identified several new genetic ... the jawbone in patients treated with bisphosphonate drugs ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: